Showing 6,181 - 6,200 results of 18,008 for search 'significantly ((((((teer decrease) OR (larger decrease))) OR (greatest decrease))) OR (a decrease))', query time: 0.50s Refine Results
  1. 6181

    Presentation 3_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhi... by Gyeong Ho Baek (21382907)

    Published 2025
    “…</p>Results<p>NuGel (0.3% [Nu0.3] and 0.5% [Nu0.5]) was well-tolerated, with no adverse drug reactions or serious adverse events. Nu0.3 showed a significant decrease in EASI score from baseline (-12.2%, [-30.3%, 5.9%], p = 0.04). …”
  2. 6182

    Data Sheet 1_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhibi... by Gyeong Ho Baek (21382907)

    Published 2025
    “…</p>Results<p>NuGel (0.3% [Nu0.3] and 0.5% [Nu0.5]) was well-tolerated, with no adverse drug reactions or serious adverse events. Nu0.3 showed a significant decrease in EASI score from baseline (-12.2%, [-30.3%, 5.9%], p = 0.04). …”
  3. 6183

    Data Sheet 2_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhibi... by Gyeong Ho Baek (21382907)

    Published 2025
    “…</p>Results<p>NuGel (0.3% [Nu0.3] and 0.5% [Nu0.5]) was well-tolerated, with no adverse drug reactions or serious adverse events. Nu0.3 showed a significant decrease in EASI score from baseline (-12.2%, [-30.3%, 5.9%], p = 0.04). …”
  4. 6184

    Presentation 2_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhi... by Gyeong Ho Baek (21382907)

    Published 2025
    “…</p>Results<p>NuGel (0.3% [Nu0.3] and 0.5% [Nu0.5]) was well-tolerated, with no adverse drug reactions or serious adverse events. Nu0.3 showed a significant decrease in EASI score from baseline (-12.2%, [-30.3%, 5.9%], p = 0.04). …”
  5. 6185
  6. 6186
  7. 6187
  8. 6188
  9. 6189
  10. 6190
  11. 6191
  12. 6192
  13. 6193
  14. 6194

    VB2 cell fate analysis of <i>hlh-17</i>, <i>hlh-31</i>, and <i>hlh-32</i> mutant animals. by G. Robert Aguilar (13889674)

    Published 2025
    “…<p>(<b>A</b>) In <i>hlh-17/31/32</i><sup>null</sup> mutants, VB2 adopts a VB1-like NeuroPAL <i>(otIs669)</i> coloring. …”
  15. 6195
  16. 6196

    Kaplan-Meier plot. by Nand Lal Banstola (10510379)

    Published 2024
    “…</p><p>Findings</p><p>All four districts showed a decrease in case notification rates since 2015, with the steepest decline in the intervention districts. …”
  17. 6197

    Characteristics of the study sample. by Nand Lal Banstola (10510379)

    Published 2024
    “…</p><p>Findings</p><p>All four districts showed a decrease in case notification rates since 2015, with the steepest decline in the intervention districts. …”
  18. 6198

    Multivariate associations with incident leprosy. by Nand Lal Banstola (10510379)

    Published 2024
    “…</p><p>Findings</p><p>All four districts showed a decrease in case notification rates since 2015, with the steepest decline in the intervention districts. …”
  19. 6199

    Univariate associations with incident leprosy. by Nand Lal Banstola (10510379)

    Published 2024
    “…</p><p>Findings</p><p>All four districts showed a decrease in case notification rates since 2015, with the steepest decline in the intervention districts. …”
  20. 6200

    <b>Sex-specific anti-inflammatory effects of a ketogenic diet in a mouse model of allergic airway inflammation</b> by Carolyn Ekpruke (17014107)

    Published 2024
    “…Results revealed significant sex-diet interactions in lung immune cell populations, with males showing greater reductions in eosinophils, increased NKT cells, and decreased NK cells. …”